Loomis Sayles, an investment management company, released its fourth-quarter 2025 investor letter for “Small Cap Growth Fund”. A copy of the letter is available to download here. The small caps' earnings are reaccelerating in 2025, as the firm forecasted a year ago. The market also experienced a low-quality rally within the small-cap space. Against this backdrop, the Small Cap Growth Fund underperformed the Russell 2000 Growth Index benchmark in the quarter, returning 0.51% vs. 1.22% for the benchmark. Head ...

Core Insights - Generative AI is viewed as a transformative technology by Amazon's CEO Andy Jassy, indicating its potential to significantly enhance customer experiences across the company [1] - Elon Musk predicts that by 2040, humanoid robots could create a market worth $250 trillion, representing a major shift in the global economy driven by AI innovation [2][3] - Major firms like PwC and McKinsey acknowledge the multi-trillion-dollar potential of AI, suggesting a broad consensus on its economic impact [3] Company and Industry Analysis - A breakthrough in AI technology is redefining work, learning, and creativity, leading to increased interest from hedge funds and top investors [4] - There is speculation about an under-owned company that may play a crucial role in the AI revolution, with its technology posing a threat to competitors [4][6] - Prominent figures in technology and investment, including Bill Gates and Warren Buffett, recognize AI as a significant advancement with the potential for substantial social benefits [8] - The article suggests that investors may regret not owning shares in a specific AI company that is positioned to capitalize on this technological wave [9]

Company Overview - Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a key player in the medical technology sector, focusing on advanced silicone breast implants [1] Financial Performance - ESTA's Return on Invested Capital (ROIC) is -12.48%, which is significantly lower than its Weighted Average Cost of Capital (WACC) of 9.01%, indicating insufficient returns to cover capital costs [2] - The negative ROIC to WACC ratio for ESTA is -1.39, highlighting the company's challenges in generating adequate returns [2] Comparative Analysis - OrthoPediatrics Corp. (KIDS) has a ROIC of -6.27% and a WACC of 8.86%, resulting in a ROIC to WACC ratio of -0.71, which is better than ESTA's performance [3] - SI-BONE, Inc. (SIBN) shows a ROIC of -10.42% and a WACC of 7.50%, leading to a similar ROIC to WACC ratio of -1.39 as ESTA [3] - Crinetics Pharmaceuticals, Inc. (CRNX) faces a severe situation with a ROIC of -49.33% and a WACC of 4.44%, resulting in a ROIC to WACC ratio of -11.10 [4] - In contrast, LivaNova PLC (LIVN) has a positive ROIC of 10.90% and a WACC of 7.96%, achieving a favorable ROIC to WACC ratio of 1.37, indicating efficient capital utilization [4]

Summary of Establishment Labs FY Conference Call Company Overview - **Company**: Establishment Labs (NasdaqCM: ESTA) - **Industry**: Medical Devices, specifically breast implants Key Points 2025 Performance and 2026 Outlook - Establishment Labs had an outstanding performance in 2025, exceeding initial expectations with the successful launch of the Motiva implant, opening 1,500 accounts, which was beyond the original plan [9][10] - The company expects strong momentum to continue into 2026, with guidance indicating at least 30% revenue growth, aiming for a midpoint revenue of $265 million [30][31] Drivers of Success - The success in 2025 was attributed to innovative marketing strategies, including partnerships with influencers and celebrities like Meghan Trainor, which significantly increased demand [13][15] - The company has been adding new accounts consistently, with a commercial team that reportedly hasn't gone a day without adding a new account [8][10] - The Preservé launch outside the U.S. has also been successful and is expected to drive growth in 2026 [11] Pricing Strategy - The pricing strategy for Motiva has been effective, with no significant pushback from the market. The company has maintained premium pricing due to the perceived value of their products [17][18] - Surgeons are reportedly charging a premium for procedures using Motiva, with increases of 30%-50% for those surgeries [46][50] Market Dynamics - The U.S. market has shown a stable demand for Ergonomix implants, with approximately 55%-60% of sales coming from this premium product line [21] - The company anticipates that the introduction of smaller size Motiva implants will capture an additional 10% of the market [65] International Business - Establishment Labs is focusing on direct markets, which offer better economics, and has seen healthy growth in international markets [71][72] - The company is optimistic about the Chinese market, expecting to achieve a dominant share similar to other Asian markets [73] Future Innovations and Expansion - The company is preparing for the reconstruction market, which could double their total addressable market (TAM). They are awaiting FDA approval for their reconstruction products [58][60] - Establishment Labs aims to democratize breast reconstruction and improve aesthetic outcomes, which could drive further adoption [63] Margin Expansion - The company expects gross margin expansion as they shift focus to higher-margin products and reduce dependency on distribution markets [67] Strategic Leadership Changes - The transition of CFO Raj Denhoy to a strategic role within the company is seen as a move to enhance business development and innovation initiatives [32][38] Additional Insights - The company has a conservative guidance approach, learning from market dynamics as they grow in the U.S. [31] - There is potential upside in revenue projections, particularly with the Preservé product line and the minimally invasive portfolio [74][76] This summary encapsulates the key insights from the Establishment Labs FY Conference Call, highlighting the company's strong performance, strategic initiatives, and future growth potential in the breast implant market.

Core Insights - The Federal Reserve's shift from higher interest rates to potential rate cuts is expected to benefit mid-cap stocks, creating a favorable environment for growth and M&A activity in 2026 [2] - Mid-cap stocks are currently trading at a historically wide 28% discount due to years of investor preference for large- and small-cap stocks [2] - Market leadership is expanding beyond mega-cap tech, with improved earnings revisions in mid- and small-cap sectors [4] Mid-Cap Stock Analysis - Establishment Labs Holdings Inc. (NASDAQ:ESTA) reported $64.62 million in Q4 revenue, slightly above the consensus expectation of $64.12 million, driven by strong demand and market acceptance of its Preserve product [11][12] - ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) achieved GAAP revenues of $284 million for Q4 and $1.07 billion for the entire year, reflecting annual increases of 9% and 12% respectively [17] - ACAD's NUPLAZID and DAYBUE products are projected to generate significant sales, with full-year 2026 revenue forecasted between $1.22 billion and $1.28 billion [18]

Financial Performance - The company reported a net cash used in operating activities of $50.9 million for the year ended December 31, 2025, compared to $58.5 million for 2024, indicating a reduction in cash burn [424][425]. - The company expects to continue generating losses in the near term, necessitating potential additional capital raises to execute its business plan [421]. - Cash used in investing activities was $7.0 million in 2025, primarily for property and equipment related to a new manufacturing facility [426]. - The company’s net cash provided by financing activities in 2024 was significantly higher at $125.9 million, largely due to a public offering that raised $99.5 million [430]. - Foreign currency transaction gains for the year ended December 31, 2025, amounted to $6.4 million, contrasting with a loss of $8.8 million in 2024 [450]. - An immediate 10% adverse change in foreign exchange rates would impact revenues by approximately 1.8% and net loss by a similar amount [455]. - Inflation did not significantly impact the company's results of operations for the periods presented [456]. Cash and Liquidity - As of December 31, 2025, the company had an accumulated deficit of $495.8 million and cash reserves of $75.6 million, down from $90.3 million in 2024 [418]. - The company raised $40.4 million in net cash from financing activities in 2025, primarily from $24.5 million in borrowings under the Tranche D Term Loan [428]. - The company has a long-term liquidity need primarily driven by expected increases in SG&A and R&D expenses related to clinical trials and product development [420]. - As of December 31, 2025, the company had $246.4 million outstanding under its Credit Agreement, with interest rates of 9% for the first two tranches and 10% for the third and fourth tranches [433]. - Cash balances were $75.6 million and $90.3 million as of December 31, 2025, and 2024, respectively, indicating a decrease [454]. Inventory and R&D - The company has entered into an Inventory Funding Agreement allowing financing of up to $10.0 million for silicone raw material purchases [419]. - R&D costs are expensed as incurred, primarily covering personnel, materials, clinical expenses, and product development [441]. - As of December 31, 2025, a provision for inventory obsolescence of $3.9 million was recorded, compared to $4.2 million in 2024 [445]. Deferred Revenue and Tax Positions - Deferred revenue includes payments received in advance, with long-term deferred revenue classified under "Other liabilities, long-term" on the balance sheet [440]. - The company operates in multiple tax jurisdictions and recognized no material uncertain tax positions as of December 31, 2025, and 2024 [448]. Impairment and Currency Hedging - There were no impairment charges recorded for long-lived assets during the years ended December 31, 2025, and 2024 [446]. - The company has not engaged in foreign currency hedging activities, but will reassess its approach as international operations grow [455].

Core Insights - Establishment Labs Holdings Inc. (NASDAQ: ESTA) reported a revenue of approximately $64.6 million for the fourth quarter of 2025, exceeding the estimated $63.8 million, indicating strong market performance [1][6] - The company experienced a quarterly loss of $0.09 per share, which was better than the Zacks Consensus Estimate of a loss of $0.22 per share, showing improvement from a loss of $0.98 per share in the previous year [2][6] - ESTA's total revenue for the year 2025 reached $211.1 million, reflecting a significant year-over-year increase of 45.2% [3] Financial Metrics - The company has a negative price-to-earnings (P/E) ratio of -42.77 and an earnings yield of -2.34%, indicating challenges in generating positive earnings [4] - Despite these challenges, ESTA's price-to-sales ratio stands at 10.15 and its enterprise value to sales ratio is 9.80, suggesting investor confidence in its growth potential [4] - The debt-to-equity ratio is low at 0.12, indicating conservative debt usage, while a current ratio of 3.04 demonstrates strong liquidity, allowing the company to cover short-term liabilities [5][6]

Core Insights - Establishment Labs reported a strong fourth quarter and full-year 2025, driven by rapid growth in its U.S. Motiva breast implant business and improving profitability metrics [5][8] Financial Performance - The company reported a fourth-quarter net loss from operations of $3.9 million, down 79% from Q4 2024, and adjusted EBITDA of positive $5.5 million, compared to negative $13.1 million in the year-ago quarter [1] - Fourth-quarter revenue was $64.6 million, up 45.2% versus Q4 2024, with full-year 2025 revenue at $211.1 million, an increase of 27.2% over 2024 [4][8] - Gross margin for Q4 was 70.5%, up 200 basis points year over year, with full-year gross margin up 330 basis points versus 2024 [2][7] Market Performance - In the U.S., Motiva revenue was $17.3 million in Q4 and $45.6 million for 2025, with the company exiting 2025 with approximately 20% augmentation market share [3][8] - The company has onboarded over 1,500 U.S. accounts since the late-2024 launch, with strong surgeon interest in Motiva [13] Growth Drivers - The minimally invasive Preserve platform is gaining traction, targeting over 200 trained U.S. surgeons and expected to generate more than $30 million in demand in 2026 [6][16] - Management plans to expand the U.S. sales force by up to 15 representatives in 2026, focusing on experienced industry veterans [14] Future Guidance - For 2026, Establishment Labs guided revenue to $264 million to $266 million, representing 25.1% to 26.0% growth, with expectations for gross margin expansion of 200 to 300 basis points [10] - The company anticipates reaching a first positive cash flow quarter in 2026, with full-year cash flow positivity expected in 2027 [9][19] Product Development - The company submitted Motiva implants to the FDA in December 2025 for primary and revision breast reconstruction, which could effectively double its U.S. total addressable market [17] - Management expressed confidence in obtaining FDA approval for small sizes in the first half of 2026 and mentioned additional pipeline programs for future U.S. introduction [18]

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA was positive at $5.5 million, compared to a loss of $13.1 million in Q4 2024 [4][24] - The ending cash balance for 2025 was $75.6 million, indicating no need for additional capital [4] Business Line Data and Key Metrics Changes - U.S. Motiva revenue in 2025 was $45.6 million, contributing significantly to overall growth [3] - Gross margin for Q4 was 70.5%, a 200 basis point increase from the previous year, with overall gross profit margin increasing 330 basis points in 2025 [22][23] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global total sales in Q4, with strong growth in direct markets [22] - Latin America represented 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific accounted for 14.1% of sales, with improved performance in China [22][19] Company Strategy and Development Direction - The company aims to transform the breast aesthetics industry through innovation, with a focus on minimally invasive procedures like Preservé [6][12] - Plans to expand the U.S. sales force by adding up to 15 more representatives to drive market penetration [11][26] - The introduction of Motiva implants for breast reconstruction is expected to double the total addressable market in the U.S. [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026 and expects significant growth in 2027 [4][30] - The U.S. market remains healthy, with strong demand for breast augmentation procedures and a positive outlook for the minimally invasive portfolio [52][60] - The company is focused on maintaining operational momentum while preparing for future growth phases [20][21] Other Important Information - The company is actively working on FDA approvals for new products, including smaller sizes and reconstruction options, which are expected to enhance market share [18][69] - Establishment Labs is also considering refinancing options for its credit facility as it approaches the end of its term [26] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management noted strong early experiences with Preservé and Mia, indicating a positive trajectory for market growth and patient interest [33][35] Question: U.S. revenue and sales representative expansion - The company is focused on hiring experienced sales representatives to enhance market penetration and drive growth [36][38] Question: Plans for reconstruction market entry - Management highlighted the significant opportunity in the reconstruction market, with plans to expand the sales force and leverage existing relationships [40][41] Question: International growth and underlying demand - Management confirmed that international markets are showing healthy demand, with no significant one-off factors affecting growth [43][44] Question: Global market conditions and augmentation procedures - The overall market for breast augmentation procedures is healthy, with increasing interest and demand across various regions [51][54] Question: Contribution of pipeline products to revenue guidance - Reconstruction is expected to be more of a 2027 story, while Preservé is anticipated to drive significant revenue growth in 2026 [68][70]

Financial Data and Key Metrics Changes - Q4 2025 revenue was $64.6 million, a 45.2% increase compared to Q4 2024, with total revenue for 2025 reaching $211.1 million, up 27.2% from 2024 [3][4] - Q4 net loss from operations was $3.9 million, down 79% from Q4 2024, while adjusted EBITDA for Q4 was $5.5 million, improving from a loss of $13.1 million in Q4 2024 [4][24] - Gross margin for Q4 was 70.5%, a 200 basis point increase from 68.5% in the previous year, with an overall gross profit margin increase of 330 basis points for 2025 compared to 2024 [22][23] Business Line Data and Key Metrics Changes - US Motiva revenue in 2025 was $45.6 million, significantly exceeding expectations, contributing to approximately 20% market share by the end of 2025 [5][6] - The minimally invasive breast augmentation platform, Preserve, is expected to generate over $30 million in demand in 2026, with strong early adoption and interest from both patients and surgeons [15][20] - The company has onboarded over 1,500 accounts since the launch of Motiva, with continued growth in the number of practices [9][11] Market Data and Key Metrics Changes - Sales in Europe, the Middle East, and Africa accounted for 41% of global sales in Q4, with over 20% growth in direct markets [22][23] - Latin America contributed 18% of sales, with stable results in Brazil and strong growth in Argentina [22][23] - Asia Pacific represented 14.1% of sales, with improved performance in China noted as a key focus area [22][19] Company Strategy and Development Direction - The company aims to expand its US sales force by adding up to 15 more representatives, focusing on experienced industry veterans to drive market penetration [11][38] - Establishment Labs is positioning itself as a leader in breast aesthetics through innovation and a strong R&D pipeline, with plans to introduce new products and expand into reconstruction markets [6][17] - The company is actively working on FDA approvals for new products, including Motiva implants for breast reconstruction, which could double the total addressable market in the US [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow positivity in 2026, with expectations for significant earnings growth in 2027 and beyond [4][30] - The overall market for breast augmentation procedures is healthy, with increasing interest and demand noted from both patients and surgeons [52][54] - The company is focused on maintaining operational momentum while ensuring strong leadership and oversight for future growth initiatives [20][21] Other Important Information - The company has a strong cash balance of $75.6 million, indicating no immediate need for additional capital [4][26] - Establishment Labs is working towards inclusion in various indices, including the Russell, which could enhance visibility and shareholder value [28] Q&A Session Summary Question: Thoughts on the minimally invasive portfolio and market growth - Management highlighted strong early experiences with Preserve and Mia, indicating optimism for market growth and potential to double breast augmentation procedure volumes [33][35] Question: Plans for expanding the US sales force - The company is focused on hiring experienced reps from the industry, which is expected to drive productivity and market share growth [36][38] Question: Insights on the reconstruction market and FDA approval - Management indicated that reconstruction is likely a 2027 story, with strong interest from hospitals already noted [40][42] Question: International growth and underlying demand - Management confirmed that international markets are performing well, with no significant one-offs affecting growth, and demand remains stable [43][45] Question: Global market outlook and macroeconomic conditions - Management noted that the underlying markets are healthy, with strong growth in both US and international markets, particularly in direct markets [51][54] Question: Contribution of new products to revenue guidance - Management indicated that while reconstruction may not significantly impact 2026, Preserve is expected to drive substantial revenue growth [68][70] Question: Spending cadence and operational expenses - Management expects spending to be non-linear, with a potential increase in the back half of the year as they support US expansion [72][74]